Demonstrates the feasibility and outlines the technical considerations of leadless pacemaker implantation in a small (18 kg) pediatric patient.
Permanent cardiac pacing in pediatric patients can be challenging secondary to patient size and associated congenital cardiac anomalies. Leadless pacemakers were developed to avoid lead-related complications associated with transvenous and epicardial pacemaker systems, and they provide an alternative approach in the pediatric population. To date, the Micra Transcatheter Pacing System (TPS) (Medtronic, Minneapolis, MN)1 is the only available Food and Drug Administration–approved system. Herein we describe a case of a leadless pacemaker implant in an 18-kilogram pediatric patient.
Gallotti et al. (Wed,) studied this question.